A0A4W2BVI6 (A0A4W2BVI6_BOBOX) Bos indicus x Bos taurus (Hybrid cattle)

Beta-lactoglobulin UniProtKBInterProInteractive Modelling

178 aa; Sequence (Fasta) ; 1 identical sequence: Bos taurus: P02754

Available Structures

97 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Crystal Structure of a Recombinant IgE Fab Fragment in Complex with Bovine Beta-Lactoglobulin Aller… Heteromer
P02754;
20-178
100LMT;
Bovine beta-lactoglobulin complex with myristic acidhomo-2-mer17-178
100.0MYR;GOL;
Bovine beta-lactoglobulin variant A at pH 4.0homo-2-mer17-178
98.77NO3;
Bovine beta-lactoglobulin complex with linoleic acidhomo-2-mer17-178
100.0EIC;GOL;EOH;
Bovine beta-lactoglobulin complex with stearic acidhomo-2-mer17-178
100.0STE;EOH;
Bovine beta-lactoglobulin (isoform A) in complex with dodecyltrimethylammonium (DTAC)homo-2-mer17-178
98.73CAT;
Engineered beta-lactoglobulin: variant L58Fhomo-2-mer17-178
98.09ACT;
Bovine beta-lactoglobulin (isoform B) in complex with dodecyltrimethylammonium (DTAC)homo-2-mer17-178
100.0CAT;GOL;
Bovine beta-lactoglobulin complex with tetracaine (BLG-TET)homo-2-mer17-178
100.0TE4;
Bovine beta-lactoglobulin (isoform A) in complex with lauric acid (C12)homo-2-mer17-178
98.73DAO;
12-BROMODODECANOIC ACID BINDS INSIDE THE CALYX OF BOVINE BETA-LACTOGLOBULINhomo-2-mer17-178
98.77BRC;
STRUCTURAL BASIS OF THE TANFORD TRANSITION OF BOVINE BETA-LACTOGLOBULIN FROM CRYSTAL STRUCTURES AT …homo-2-mer17-178
98.77
Bovine beta-lactoglobulin (isoform B) in complex with dodecyl sulphate (SDS)homo-2-mer17-178
100.0SDS;GOL;
Bovine beta-lactoglobulin (isoform A) in complex with dodecyl sulphate (SDS)homo-2-mer17-178
98.73SDS;
Energetic and structural effects of the Tanford transition on the ligand recognition of bovine Beta…homo-2-mer17-178
100SDS;
STRUCTURAL BASIS OF THE TANFORD TRANSITION OF BOVINE BETA-LACTOGLOBULIN FROM CRYSTAL STRUCTURES AT …homo-2-mer17-178
98.77
Recombinant bovine beta-lactoglobulin with uncleaved N-terminal methionine (rBlgB)homo-2-mer17-178
100.0GOL;MYR;SIN;
Recombinant bovine beta-lactoglobulin variant L1A/I2S with endogenous ligand (sBlgB#1)homo-2-mer17-178
98.73MYR;
Bovine beta-lactoglobulin complex with dodecyl sulfatehomo-2-mer18-178
100.0SDS;GOL;
Mutant I56F of recombinant bovine beta-lactoglobulin in complex with tetracainehomo-2-mer18-178
98.72SO4;TE4;
Beta-lactoglobulin mutant FAW (I56F/L39A/M107W), unliganded formhomo-2-mer18-178
97.47EDO;
Engineered beta-lactoglobulin: variant F105L-L39A-M107F in complex with chlorpromazine (LG-LAF-CLP)homo-2-mer18-178
97.48Z80;
Bovine lactoglobulin complex with decanolhomo-2-mer18-178
100.0DE1;
Bovine beta-lactoglobulin complex with palmitic acidhomo-2-mer18-178
100.0PLM;EOH;
Trigonal form of WT recombinant bovine beta-lactoglobulinhomo-2-mer18-178
99.36EDO;EOH;
Bovine beta-lactoglobulin complex with lauric acidhomo-2-mer18-178
100.0DAO;CL;
Bovine beta-lactoglobulin complex with oleic acidhomo-2-mer18-178
100.0OLA;EOH;GOL;
Mutant L39Y of recombinant beta-lactoglobulin in complex with endogenous ligandhomo-2-mer18-178
98.68DAO;CL;
Engineered beta-lactoglobulin: variant F105L-L39A in complex with chlorpromazine (LG-LA-CLP)homo-2-mer18-178
98.1Z80;PO4;
Bovine beta-lactoglobulin complex with pramocaine crystallized from ammonium sulphate (BLG-PRM2)homo-2-mer18-178
100.0PX9;
BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOIC ACID, TRIGONAL LATTICE Zhomo-2-mer18-178
100REA;
BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOL AND PALMITIC ACID, TRIGONAL LATTICE Zhomo-2-mer18-178
100PLM;
BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOL, TRIGONAL LATTICE Zhomo-2-mer18-178
100RTL;
BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH PALMITATE, LATTICE Zhomo-2-mer18-178
100PLM;
Mutant F105A of recombinant beta-lactoglobulin in complex with endogenous ligandhomo-2-mer19-178
99.36DAO;SO4;
Engineered beta-lactoglobulin: variant I56Fhomo-2-mer19-178
99.36SO4;GOL;
Mutant F105L of recombinant beta-lactoglobulinhomo-2-mer19-178
99.36GOL;SO4;
Engineered beta-lactoglobulin: variant F105L in complex with myristic acidhomo-2-mer19-178
99.35MYR;EDO;
Mutant L58F of recombinant bovine beta-lactoglobulin in complex with tetracainehomo-2-mer19-178
99.35TE4;SO4;
Mutant L39Y-L58F of recombinant bovine beta-lactoglobulin in complex with pramocainehomo-2-mer19-178
98.69PX9;SO4;
Mutant L58F of recombinant bovine beta-lactoglobulin in complex with pramocainehomo-2-mer19-178
99.35PX9;SO4;
Mutant L39Y-L58F of recombinant bovine beta-lactoglobulin in complex with endogenous fatty acidhomo-2-mer19-178
98.69DAO;EDO;SO4;CL;
Engineered beta-lactoglobulin: variant M107L in complex with myristic acidhomo-2-mer19-178
99.35MYR;
Bovine beta-lactoglobulin crystallized in the presence of 2 mM zinc chloridehomo-2-mer19-178
100ZN;
Mutant L39K of recombinant beta-lactoglobulin in complex with endogenous ligandhomo-2-mer19-178
99.33DKA;EDO;
Beta-lactoglobulin (low humidity)homo-2-mer17-176
98.75
Engineered beta-lactoglobulin: variant L39Y in complex with endogenous ligandhomo-2-mer19-178
99.33PLM;EDO;
Mutant L39Y of recombinant bovine beta-lactoglobulin in complex with pramocainehomo-2-mer19-178
99.32PX9;SO4;CL;
Engineered beta-lactoglobulin: variant I56F-L39A in complex with chlorpromazine (LG-FA-CLP)homo-2-mer19-178
98.72Z80;
Beta-lactoglobulin mutant FAW (I56F/L39A/M107W) in complex with desipramine (FAW-DSM#2)homo-2-mer20-178
98.08EDO;DSM;SO4;CL;
Engineered beta-lactoglobulin: variant I56F-L39A-M107F in complex with chlorpromazine (LG-FAF-CLP)homo-2-mer20-178
98.06Z80;SO4;GOL;PO4;CL;
Beta-lactoglobulin mutant FAF (I56F/L39A/M107F) in complex with desipramine (FAF-DSM)homo-2-mer20-178
98.1DSM;GOL;CL;EDO;SO4;
Beta-lactoglobulin mutant FAW (I56F/L39A/M107W) in complex with desipramine (FAW-DSM#1)homo-2-mer20-178
98.08SO4;DSM;CL;EDO;
Beta-lactoglobulin mutant FAF (I56F/L39A/M107F), unliganded formhomo-2-mer19-177
98.03SO4;
Bovine beta-lactoglobulin crystallized in the presence of 20 mM zinc chloridehomo-2-mer20-178
100ZN;
Beta-lactoglobulin mutant FAW (I56F/L39A/M107W) in complex with desipramine (FAW-DSM#3)homo-2-mer20-177
98.1DSM;EDO;SO4;CL;
Mutant M107L of recombinant bovine beta-lactoglobulin in complex with tetracainehomo-2-mer21-178
99.35TE4;
The Cys121Ser Mutant of Beta-Lactoglobulinhomo-2-mer17-174
98.1
Engineered beta-lactoglobulin: variant M107Lhomo-2-mer19-176
99.31GOL;PO4;
Bovin Beta-lactoglobulin binding with zinc ionshomo-2-mer22-178
100ZN;
Recombinant bovine beta-lactoglobulin variant L1A/I2S (sBlgB#2)homo-2-mer17-173
98.66
The structure of bovine B-lactoglobulin A in crystals grown at very low ionic strengthhomo-2-mer21-176
98.72
HIGH RESOLUTION CRYSTAL STRUCTURE OF THE BOVINE BETA-LACTOGLOBULIN (ISOFORM A)homo-2-mer17-170
98.68
HIGH RESOLUTION CRYSTAL STRUCTURE OF THE BOVINE BETA-LACTOGLOBULIN (ISOFORMS A AND B) IN ORTHOROMBI…homo-2-mer17-168
100
Beta-lactoglobulin (native)homo-2-mer17-168
98.68
Engineered beta-lactoglobulin: variant F105Lhomo-2-mer17-168
97.76
Beta-lactoglobulin (reverse native)homo-2-mer17-168
98.68
Crystal structure of Gyuba, a patched chimera of b-lactglobulinhomo-2-mer34-170
100
Bovine beta-lactoglobulin complex with capric acidmonomer17-178
100DKA;GOL;CL;
Bovine beta-lactoglobulin complex with caprylic acidmonomer17-178
100OCA;CL;
Thermodynamic, Crystallographic and Computational Studies of Non Mammalian Fatty Acid Binding to Bo…monomer17-178
100TDA;
Thermodynamic, Crystallographic and Computational Studies of Non Mammalian Fatty Acid Binding to Bo…monomer17-178
100F15;CL;
Bovine beta-lactoglobulin complex with pramocaine crystallized from sodium citrate (BLG-PRM1)monomer17-178
100.0PX9;
Crystal structure of the Cisplatin beta-Lactoglobulin adduct formed after 18 h of soakingmonomer17-178
99.38NH3;PT;
Crystal structure of the Cisplatin beta-Lactoglobulin adduct formed after 72 h of soakingmonomer17-178
100NH3;PT;
Bovine beta lactoglobulin unliganded formmonomer17-178
100
STRUCTURAL AND FUNCTIONAL CONSEQUENCES OF POINT MUTATIONS OF VARIANTS A AND B OF BOVINE BETA-LACTOG…monomer17-178
100
Thermodynamic, Crystallographic and Computational Studies of Non Mammalian Fatty Acid Binding to Bo…monomer17-178
100EW8;
Bovine beta-lactoglobulin complex with myristic acid at high pressure (0.55 GPa)monomer17-178
100MYR;
STRUCTURAL BASIS OF THE TANFORD TRANSITION OF BOVINE BETA-LACTOGLOBULIN FROM CRYSTAL STRUCTURES AT …monomer17-178
98.77
Crystal structure of beta-lactoglobulin complexed with chloroquinemonomer17-178
98.770TX;
Bovine beta-lactoglobulin complex with myristic acid, ambient pressuremonomer17-178
100MYR;
Unliganded form of bovine beta-lactoglobulin, ambient pressuremonomer17-178
100CL;
Bovine beta-lactoglobulin complex with dodecane at high pressure (0.43 GPa)monomer17-178
100D12;CL;
Energetic and structural effects of the Tanford transition on the ligand recognition of bovine Beta…monomer18-178
100.0SDS;
Beta-lactoglobulin in complex with Cp*Rh(III)Cl N,N-di(pyridin-2-yl)dodecanamidemonomer18-178
98.72RHL;
Thermodynamic, Crystallographic and Computational Studies of Non Mammalian Fatty Acid Binding to Bo…monomer18-178
100X90;
Crystal structure of a secondary vitamin D3 binding site of milk beta-lactoglobulinmonomer18-178
100VD3;
Bovine beta lactoglobulin crytsallized through ligandation of yttriummonomer18-178
100YT3;CL;
X.ray structure of the oxaliplatin/beta-lactoglobulin adductmonomer19-178
100PT;
Engineered beta-lactoglobulin: variant L58F in complex with myristic acidmonomer19-178
99.32MYR;SO4;
The structure of bovine beta-lactoglobulin in novel crystals grown at pH 3.8monomer18-177
100CA;
BOVINE BETA-LACTOGLOBULIN Amonomer19-178
98.75
STRUCTURAL CHANGES ACCOMPANYING PH-INDUCED DISSOCIATION OF THE B-LACTOGLOBULIN DIMERmonomer19-178
98.75
Bovine beta lactoglobulin crystallized through ligandation of yttrium cationsmonomer20-178
100YT3;CL;
Crystal structure of dha bind to bovine beta-lactoglobulinmonomer20-178
100
BOVINE BETA-LACTOGLOBULIN, LATTICE Xmonomer21-176
99.36

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6nkq.1.Amonomer0.8618-177
CA;100.00